Pfizer to Sell Georgia Manufacturing Plant to Xethanol
Xethanol Corporation's (New York, NY) subsidiary CoastalXethanol signed a letter of intent with Pfizer Inc. (New York, NY) to purchase Pfizer's pharmaceutical manufacturing complex in Augusta, Georgia.
Xethanol Corporation's (New York, NY, www.xethanol.com) subsidiary CoastalXethanolsigned a letter of intent with Pfizer Inc. (New York, NY, www.pfizer.com) topurchase Pfizer's pharmaceutical manufacturing complex in Augusta,Georgia.
The 40-acre site includes an 89,100-ft2 manufacturingfacility, a25,000-ft2 warehouse facility, 7300-ft2 oflaboratory space, and 16,000-ft2 of offices and conference rooms. CoastalXethanol intends to retrofit the site to produce 35 million gallons per year of ethanol.
The facility will produce ethanol from cellulosic and other biomasswaste streams generated by industrial producers in the surroundingareas. CoastalXethanol may produce biodiesel in this facility underXethanol's sublicense from H2Diesel, Inc.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
